ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ)
$2.25 0 (0%)
Analysed ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ) News Sources
William Blair Initiates Natera (NTRA) With Outperform
02-05-2026
yahoo.com
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
06-05-2026
yahoo.com
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
13-05-2026
yahoo.com
Allogene Therapeutics Q1 2026 Earnings Call Transcript
13-05-2026
yahoo.com
Allogene Therapeutics Q1 Earnings Call Highlights
14-05-2026
marketbeat.com
Allogene Therapeutics Inc (ALLO) Q1 2026 Earnings Call Highlights: Promising Trial Results and ...
14-05-2026
yahoo.com
Big Pharma’s 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
14-05-2026
247wallst.com
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1
14-05-2026
yahoo.com
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
26-05-2026
yahoo.com
Allogene Therapeutics Announces Planned CEO Succession
28-05-2026
yahoo.com
What is the current price of ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ)?
The current price of ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ) is $2.25.
ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ) absolute price change since previous trading day?
The absolute price change of ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ) since the previous trading day is $0.
ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ) percentage price change since previous trading day?
The percentage price change of ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ) since the previous trading day is 0%.
What is the most recent average sentiment score for ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ)?
The most recent average sentiment score for ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ) is 80 out of 100.
What is the most recent average sentiment for ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ)?
The most recent sentiment for ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ) is .
SEC-8K** Filing Available For ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.